ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Lp(a) and Long-Term CV Risk in a Pooled CohortWhat is the long-term implication of lipoprotein(a) [Lp(a)] elevation in a pooled multi-ethnic US cohort?
- ACC CardiaCast: Courtside with the Chair: Shared Decision-Making with Athletes: A Discussion of ‘Why’? Part 2In Part 2, Dr. Jonathan Kim continues the conversation with Drs. Maron, Harmon, and Baggish discussing the principles of shared decision-making in the context of sports participation for athletes with heart disease and ‘the why’ to do it.
- Genotype-First Approach to Cardiomyopathy OutcomesWhat is the risk of mortality and composite cardiomyopathy-related outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes?
- SGLT2 Inhibitors and Major Adverse CV OutcomesWhat is the effect of sodium glucose co-transporter 2 inhibitors (SGLT2i) on the risk of major adverse cardiovascular events (MACE) and its individual components, overall and within clinically relevant subgroups of patients, irrespective of atherosclerotic cardiovascular disease (ASCVD), diabetes, and kidney function?
- FDA Update: Heartmate II and Heartmate 3 LVAS Recalled Due to ObstructionThe U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term buildup of biological material causing an obstruction in the device, making it more difficult for the heart to pump blood.